Immune recognition of self in immunity against cancer

Alan N. Houghton and José A. Guevara-Patiño

The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Most antigens expressed by human cancer cells and recognized by host T cells and antibodies are nonmutated self antigens — molecules also expressed on the surface of normal cells. These self antigens are ineffective at triggering immune responses against cancer cells, which provides one explanation for the difficulties in trying to immunize against human cancer. A new study describes how tumors can avoid recognition by the immune system and how enhancing the affinity of the interaction between a self antigen and the MHC-I molecule may lead to cancer immunity (see the article appearing on page 551).

The self/nonself paradigm

Immunologists generally agree that the immune system was shaped through evolution by the necessity of discriminating nonself pathogens from self tissues (1). This distinction is extremely important for the survival of multicellular organisms. Some strategies for the recognition of nonself pathogens are clear-cut. For example, receptors such as toll-like receptors on host leukocytes bind to certain bacterial or fungal molecules, leading to mobilization of host defenses by signaling the synthesis of molecules that initiate innate and adaptive immune responses. The adaptive immune system, with its diversity of T cell receptors (TCRs) and antibodies, uses even more precise mechanisms for the recognition of nonself pathogens. This view of self/nonself provides a logical and useful description of how the immune system responds to exogenous microbes that cause disease.

Recognition of cancer by the host’s immune system

Understanding and achieving immunity to cancer does not fit neatly into the self/nonself paradigm because cancer is not an exogenous pathogen, but rather arises from normal host cells. In this regard, cancer antigens recognized by the human immune system are self or mutated self molecules (2). Explaining the genetic basis for the pathogenesis of cancer is necessary to understanding the difficulties that the immune system has in recognizing cancer cells.

Protooncogenes and tumor suppressor genes are normal cellular genes that control crucial cell functions, particularly growth and survival (3). Mutations in these genes lead to the emergence of cancer. In addition, loss of expression of tumor suppressor genes contributes to malignant transformation through major deletions in their genetic sequences or silencing by methylation of nucleotides in promoter regions that control gene expression. These deleted or silent genes are incapable of producing antigenic targets for the immune system, but mutated protooncogenes, tumor suppressor genes, or other self genes might generate mutant protein products that could serve as suitable antigens.

An accumulation of genetic alterations in protooncogenes and tumor suppressor genes leads to profound changes in normal cells, including immortalization, a block in terminal differentiation, an ability to invade normal tissues and recruit new blood vessels, and the potential to metastasize to distant organs (3). However, because the immune system is trained not to respond to self molecules (in order to avoid autoimmunity), antigenic changes in malignant cells that are created by individual mutations can be rather subtle from the standpoint of the immune system — cancer cells still utilize essentially the same cellular molecules as healthy cells to regulate growth and survival (3). Perhaps mutations in self proteins can be viewed as generating nonself proteins, comparable to foreign proteins from pathogens or other species. This argument has been used as the basis for conducting experiments in mice for the study of tumor immunity using tumors expressing viral or chicken proteins.

T cells, which are immune cells crucial for rejecting tumors, use their TCRs to recognize short antigenic peptides bound...
T cell–dependent immunity against mutated self antigens on tumors

Can cancer cells with mutated self peptides stimulate host T cells? As few as two or three distinct mutations in different cellular protooncogenes can induce malignant transformation and tumorigenicity of normal rodent cells (3, 4). In this reductionist view, a total of only two mutations in two different cellular proteins produce tumors. The problem for host T cells becomes searching for these two mutations against the backdrop of the thousands of nonmutated proteins in the cell—which is like searching for a needle in a haystack. The reader may be aware that T cells can use their TCRs to discriminate even single amino acid changes in peptides. Thus, activated T cells might be capable of surveying for cancer cells expressing rare mutated self peptides bound to MHC-I or -II molecules, leading to destruction of those cells. In support of this argument, classical experiments in mice have shown that T cells are capable of rejecting mutagen-induced tumors (5). For tumors in mice induced by exposure to strong mutagens, T cell–dependent immunity is directed against antigens that are mutated self peptides (6, 7).

Do T cell responses to mutated self antigens reveal how immunity against cancer is generated? Not exactly. Tumors that are elicited by short, intense exposure of rodents to potent carcinogens carry large numbers of mutations, and these tumors arise over weeks or several months. These experimental models do not adequately reflect the pathogenesis of most human cancers, which result from multiple discrete mutations accumulated sequentially over decades (3).

Immunity against nonmutated self antigens on cancer cells

Although the repertoire of T cells in humans can recognize both self and mutated self peptides on human cancer cells, T cells and antibodies from cancer patients have been shown to recognize largely nonmutated self antigens (2). The widespread T cell recognition of self antigens on human cancer cells is surprising. Insights into the relevance of T cell recognition of nonmutated self antigens have stemmed from studies of spontaneous tumors in mice. These tumors are weakly immunogenic, yet arguably are more representative of most human cancers than the strongly immunogenic mutagen-induced tumors (5, 8).
T cells can reject weakly immunogenic spontaneous tumors by recognizing nonmutated self antigens as long as special strategies are used for immunization (9–13). How could T cells be triggered to reject tumors expressing weak self antigens? The answer starts with understanding how the repertoire of host T cells is selected during development. Any immature T cell with high-affinity TCRs for a self antigen is deleted during its early development in the thymus; this process leads to destruction of more than 90% of immature T cells. Elimination of these high-affinity T cells is necessary to avoid the development of autoimmunity. However, despite this stringent selection, the immune repertoire is replete with naive, self-reactive T cells that have TCRs with relatively low affinity for self antigens. These weak self antigens are incapable of inducing immune responses. However, if T cells against these apparently ineffective self antigens can somehow be activated through vaccination or other means, then these T cells can reject tumors presenting these antigens (9–13).

**A role for mutated peptides in eliciting immunity against nonmutated self antigens**

Experimental evidence in mice has previously shown that poorly immunogenic spontaneous tumors can be converted to strongly immunogenic tumors by intense exposure to mutagens (14, 15). Remarkably, immunity against mutagenized tumors also yields T cell–dependent immunity against the parental nonmutagenized tumor. How might mutations in self peptides induce T cell responses against weak self antigens? One potential mechanism relies on point mutations that increase peptide binding to MHC-I molecules, leading to immunity against the nonmutated self peptides presented by tumor cells (Figure 1). The paper by Yu et al. in this issue of the *JCI* demonstrates the relevance of this mechanism to cancer immunity (16).

Selected missense mutations in self peptides increase peptide binding to MHC-I or -II molecules by altering single amino acid residues that anchor the peptide to the MHC molecule. Enhanced binding of the mutant peptides to MHC molecules provides more favorable energy conditions at the APC/TCR synapse for T cell activation. These mutations increase the surface density of self peptides at this synapse on the surface of APCs through increased affinity for MHC molecules (Figure 1). These missense mutations are not really nonself, but rather have been termed altered self (17).

Some missense mutations in self peptides increase TCR signaling sufficiently to trigger activation of naive T cells (Figure 1). Once these T cells are primed, they may respond to the parental nonmutant peptide presented by cancer cells and normal cells. Such antigens have been called heteroclitic. Previous experiments have shown that vaccination with a mutant form of a nonimmunogenic peptide, rationally designed to enhance binding to MHC-I molecules, leads to T cell–dependent rejection of tumors expressing the parental nonmutant peptide (18). Furthermore, other reports have shown that vaccination using molecules from other species, specifically immunizing with poly peptides to host MHC-I molecules, generates T cell responses against poorly immunogenic spontaneous tumors expressing only nonmutated self antigens (9–13).

**Host T cells ignore cancer cells expressing weak self antigens**

In this issue of the *JCI*, Yu and colleagues provide important insights into how tumor cells expressing a weak self antigen avoid recognition by host T cells (16). Three possible mechanisms for tumor escape from T cell immunity are explored: (a) insufficient numbers of host T cells against the self antigen are present in the T cell repertoire; (b) immune tolerance of T cells occurs through anergy (a permanent state of T cell inactivation), T cell deletion, or suppression by host regulatory cells; or (c) naive T cells against the self peptide ignore antigen-positive cells because of inadequate affinity of self peptide for host MHC molecules.

To address these possibilities, Yu et al. have created a remarkable strain of transgenic mice engineered to express both human TCR chains against an antigenic peptide in T cells and human MHC-I domains broadly in somatic cells (16). The antigenic peptide recognized by the human TCRs is expressed by both human and mouse melanoma cells and melanocytes (normal pigment cells in the epidermis and other tissues). Because the MHC-I domains, TCR chains, and antigenic peptide are of human origin, this humanized mouse system has direct relevance to the generation of T cell immunity against human melanoma. The 9 amino acid, wild-type self peptide has low affinity for MHC-I molecules and elicits minimal or no responses in naive T cells. In contrast, a heteroclitic mutated peptide, which contains a single amino acid substitution that generates a 6-fold improved affinity of the peptide for MHC-I molecules, activates naive host T cells (Figure 1). Tumor rejection only occurs following immunization with heteroclitic peptide; wild-type peptide is ineffective.

This report demonstrates that improvements in the affinity of the peptide/MHC-I interaction can overcome the barrier to priming T cell–mediated immunity against weak self antigens. In this system, naive T cells expressing TCRs against wild-type self peptide ignore melanoma cells presenting this peptide because of the low affinity of the peptide for MHC-I molecules. The authors clearly show that this lack of T cell responsiveness is not due to insufficient numbers of T cells, T cell deletion, anergy, or other tolerance mechanisms (16). These results have relevance for development of experimental vaccines for the treatment of human cancer, demonstrating that careful attention needs to be paid to the affinity of potential antigenic peptides for MHC molecules.

**Concluding remarks**

Overcoming the barriers to the generation of immunity against self and mutated self antigens is a central concern for the ongoing efforts to treat cancer using active immunization. Inducing immunity against self antigens is dangerous territory because of the potential for autoimmunity. However, treatments using passive immunization with monoclonal antibodies against self antigens have already been successful in objectively shrinking established tumors in patients with cancer, without serious toxicities (e.g., the administration of rituximab, which is active against CD20 on the surface of B cells for the treatment of patients with lymphoma) (19, 20).

The self/nonself paradigm describes immunity against microbial pathogens but does not adequately portray adaptive immunity to cancer. We have proposed a self/alterned-self paradigm as a more appropriate description of immune responses to self and mutated self antigens on cancer cells (17). The results of Yu et al. and other reports raise a series of questions (6, 7, 9–16). How frequently are mutations recognized? What types of mutations enhance T cell responses against nonmutated self peptides? How might the immune system have evolved to recognize not only pathogens but also cancer cells (in the context of self/alterned self)? We believe that the answers to these questions are important to understanding cancer immunity and perhaps autoimmunity.
The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis

Gary S. Firestein
Division of Rheumatology, Allergy, and Immunology and Clinical Investigation Institute, University of California San Diego School of Medicine, San Diego, California, USA.

The etiology of autoimmunity in humans remains poorly defined, and animal models provide a unique opportunity to study potential autoimmune mechanisms. A novel model of autoimmune inflammatory arthritis results from a point mutation in the ζ-associated protein of 70 kDa (ZAP-70), which causes abnormal thymic T cell selection and survival of autoreactive clones (see the related article beginning on page 582). Although the resulting clinical and pathologic abnormalities are clearly T cell–dependent, macrophage and fibroblast cytokines such as IL-1 and TNF-α are required for full expression of the disease. The studies of Hata et al. raise the intriguing possibility that traditional proinflammatory cytokine networks represent common effector mechanisms in inflammatory joint diseases such as rheumatoid arthritis. Hence, effective therapeutic interventions can target either unique etiologic pathways related to adaptive immune responses or shared terminal mechanisms.

Nonstandard abbreviations used: ζ-associated protein of 70 kDa (ZAP-70); collagen-induced arthritis (CIA); cyclic citrullinated peptide (CCP); Grb2-associated binder 2 (Gab2); linker for activation of T cells (LAT); lymphocyte protein tyrosine kinase (Lck); rheumatoid arthritis (RA); SH2-domain-containing leukocyte protein of 76 kDa (SLP-76); Src homology 2 (SH2); vaccinia virus V11-related (VHR).

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 114:471–474 (2004). doi:10.1172/JCI200422651.